Abstract
Asbestos-related diseases (ARDs) resulting from exposure to asbestos include lung cancer and malignant mesothelioma (MM). This has significant health and economic implications that have been well documented. The 20–40-year latency periods of ARDs and their low incidence rates in the general population make preventative strategies and early treatment extremely challenging. The availability of well-validated diagnostic biomarkers of asbestos exposure would greatly facilitate both prevention and early treatment strategies. In this chapter, we have summarized the state of knowledge on biomarkers of response to asbestos exposure and highlighted recent advances, including the discovery of new specific biomarker based on the posttranslational modifications of the high mobility group box 1 (HMGB1) protein. Asbestos is inhaled and trapped primarily in lung tissue and so can only be detected in bronchoalveolar lavage fluid. This makes direct exposure assessments very difficult. In contrast, biomarkers of response, which reflect a change in biologic function in response to asbestos exposure, have proved to be more useful. MM is the major biological response to asbestos that can be readily monitored, and numerous studies have used this disease as confirmation of a prior asbestos exposure. There is some new evidence that an increase in serum nonacetylated HMGB1 can serve as a biological response biomarker of asbestos exposure; whereas acetylated serum HMGB1 is associated with progression to MM. Finally, we discuss the potential merit of combined use of a multiplexed serum lipid biomarker panel with serum protein biomarkers.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Altomare DA, Menges CW, Xu J et al (2011) Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS One 6:e18828
Antoine DJ, Jenkins RE, Dear JW et al (2012) Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol 56:1070–1079
Armstrong AW, Voyles SV, Armstrong EJ et al (2011) Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis. J Dermatol Sci 63:1–9
Bang KM, Mazurek JM, Storey E et al (2009) Malignant mesothelioma mortality-United States, 1999–2005. MMWR Morb Mortal Wkly Rep 58:393–396
Barnay-Verdier S, Gaillard C, Messmer M et al (2011) PCA-ELISA: a sensitive method to quantify free and masked forms of HMGB1. Cytokine 55:4–7
Bayram M, Dongel I, Akbas A et al (2014) Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. Lung 192:197–203
Becklake MR (1976) Asbestos-related diseases of the lung and other organs: their epidemiology and implications for clinical practice. Am Rev Respir Dis 114:187–227
Bergmann C, Strohbuecker L, Lotfi R et al (2016) High mobility group box 1 is increased in the sera of psoriatic patients with disease progression. J Eur Acad Dermatol Venereol 30:435–441
Beyer HL, Geschwindt RD, Glover CL et al (2007) MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 53:666–672
Bianchi AB, Mitsunaga SI, Cheng JQ et al (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 92:10854–10858
Blair IA (2008) DNA adducts with lipid peroxidation products. J Biol Chem 283:15545–15549
Bonaldi T, Talamo F, Scaffidi P et al (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22:5551–5560
Boulanger G, Andujar P, Pairon JC et al (2014) Quantification of short and long asbestos fibers to assess asbestos exposure: a review of fiber size toxicity. Environ Health 13:59
Britton M (2002) The epidemiology of mesothelioma. Semin Oncol 29:18–25
Carbone M, Flores EG, Emi M et al (2015) Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred tracing back nine generations to a common ancestor from the 1700s. PLoS Genet 11:e1005633
Carbone M, Ly BH, Dodson RF et al (2012) Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 227:44–58
Carbone M, Yang H, Pass HI et al (2013) BAP1 and cancer. Nat Rev Cancer 13:153–159
Ceresoli GL, Bonomi M, Sauta MG (2016) Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges. Expert Rev Anticancer Ther 16:673–675
Chen G, Li J, Qiang X et al (2005) Suppression of HMGB1 release by stearoyl lysophosphatidylcholine: an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res 46:623–627
Cheng JQ, Jhanwar SC, Klein WM et al (1994) p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54:5547–5551
Cheresh P, Morales-Nebreda L, Kim SJ et al (2015) Asbestos-induced pulmonary fibrosis is augmented in 8-oxoguanine DNA glycosylase knockout mice. Am J Respir Cell Mol Biol 52:25–36
Cheung M, Talarchek J, Schindeler K et al (2013) Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet 206:206–210
Chew SH, Toyokuni S (2015) Malignant mesothelioma as an oxidative stress-induced cancer: an update. Free Radic Biol Med 86:166–178
Corradi M, Goldoni M, Alinovi R et al (2013) YKL-40 and mesothelin in the blood of patients with malignant mesothelioma, lung cancer and asbestosis. Anticancer Res 33:5517–5524
Creaney J, Dick IM, Robinson BW (2015) Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma. Curr Opin Pulm Med 21:352–356
Creaney J, Musk AW, Robinson BW (2010a) Sensitivity of urinary mesothelin in patients with malignant mesothelioma. J Thorac Oncol 5:1461–1466
Creaney J, Olsen NJ, Brims F et al (2010b) Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomark Prev 19:2238–2246
Cui A, Jin XG, Zhai K et al (2014) Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open 4:e004145
de Assis LV, Locatelli J, Isoldi MC (2014) The role of key genes and pathways involved in the tumorigenesis of malignant mesothelioma. Biochim Biophys Acta 1845:232–247
Demir M, Kaya H, Taylan M et al (2016) Evaluation of new biomarkers in the prediction of malignant mesothelioma in subjects with environmental asbestos exposure. Lung 194:409–417
Denhardt DT, Chambers AF (1994) Overcoming obstacles to metastasis--defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem 56:48–51
Ellegaard PK, Poulsen HE (2016) Tobacco smoking and oxidative stress to DNA: a meta-analysis of studies using chromatographic and immunological methods. Scand J Clin Lab Invest 76:151–158
Felten MK, Khatab K, Knoll L et al (2014) Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers. Int Arch Occup Environ Health 87:195–204
Frank AL, Joshi TK (2014) The global spread of asbestos. Ann Glob Health 80:257–262
Fung H, Kow YW, Van HB et al (1997) Patterns of 8-hydroxydeoxyguanosine formation in DNA and indications of oxidative stress in rat and human pleural mesothelial cells after exposure to crocidolite asbestos. Carcinogenesis 18:825–832
Ge X, Antoine DJ, Lu Y et al (2014) High Mobility Group Box-1 (HMGB1) participates in the pathogenesis of alcoholic liver disease (ALD). J Biol Chem 289:22672–22691
Grigoriu BD, Scherpereel A, Devos P et al (2007) Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 13:2928–2935
Guo Y, Chirieac LR, Bueno R et al (2014) Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma. Oncogene 33:3151–3160
Hanaoka T, Tsugane S, Yamano Y et al (1993) Quantitative analysis of 8-hydroxyguanine in peripheral blood cells: an application for asbestosis patients. Int Arch Occup Environ Health 65:S215–S217
Hillegass JM, Miller JM, Macpherson MB et al (2013) Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells. Part Fibre Toxicol 10:39
Hillegass JM, Shukla A, Lathrop SA et al (2010) Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y Acad Sci 1203:7–14
Hu ZD, Liu XF, Liu XC et al (2014) Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis. Clin Chim Acta 433:44–48
Jakubec P, Pelclova D, Smolkova P et al (2015) Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 159:472–479
Jube S, Rivera ZS, Bianchi ME et al (2012) Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 72:3290–3301
Kadiiska MB, Gladen BC, Baird DD et al (2005) Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 38:698–710
Kalra N, Zhang J, Thomas A et al (2015) Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. BMC Cancer 15:376
Kirschner MB, Pulford E, Hoda MA et al (2015) Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. Br J Cancer 113:963–969
Kovac V, Dodic-Fikfak M, Arneric N et al (2015) Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma. Radiol Oncol 49:279–285
Lang-Lazdunski L (2014) Surgery for malignant pleural mesothelioma: why, when and what? Lung Cancer 84:103–109
Lemen RA, Dement JM, Wagoner JK (1980) Epidemiology of asbestos-related diseases. Environ Health Perspect 34:1–11
Lievense LA, Hegmans JP, Aerts JG (2014) Biomarkers for immune checkpoint inhibitors. Lancet Oncol 15:e1
Linton A, Vardy J, Clarke S et al (2012) The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma. Crit Rev Oncol Hematol 84:200–212
Lotze MT, Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5:331–342
Marczynski B, Kraus T, Rozynek P et al (2000a) Association between 8-hydroxy-2′-deoxyguanosine levels in DNA of workers highly exposed to asbestos and their clinical data, occupational and non-occupational confounding factors, and cancer. Mutat Res 468:203–212
Marczynski B, Rozynek P, Kraus T et al (2000b) Levels of 8-hydroxy-2′-deoxyguanosine in DNA of white blood cells from workers highly exposed to asbestos in Germany. Mutat Res 468:195–202
Marini V, Michelazzi L, Cioe A et al (2011) Exposure to asbestos: correlation between blood levels of mesothelin and frequency of micronuclei in peripheral blood lymphocytes. Mutat Res 721:114–117
Mesaros C, Arora JS, Wholer A et al (2012) 8-Oxo-2′-deoxyguanosine as a biomarker of tobacco-smoking-induced oxidative stress. Free Radic Biol Med 53:610–617
Mesaros C, Blair IA (2016) Mass spectrometry-based approaches to targeted quantitative proteomics in cardiovascular disease. Clin Proteomics 13:20
Mesaros C, Worth AJ, Snyder NW et al (2015) Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure. Bioanalysis 7:1157–1173
Milne GL, Musiek ES, Morrow JD (2005) F2-Isoprostanes as markers of oxidative stress in vivo: an overview. Biomarkers 10(Suppl 1):S10–S23
Montjoy C, Parker J, Petsonk L et al (2009) Mesothelioma review. W V Med J 105:13–16
Mossman BT, Shukla A, Heintz NH et al (2013) New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol 182:1065–1077
Napolitano A, Antoine DJ, Pellegrini L et al (2016) HMGB1 and its hyperacetylated isoform are sensitive and specific serum biomarkers to detect asbestos exposure and to identify mesothelioma patients. Clin Cancer Res 22(12):3087–3096
Navarro-Compan V, Melguizo-Madrid E, Hernandez-Cruz B et al (2013) Interaction between oxidative stress and smoking is associated with an increased risk of rheumatoid arthritis: a case-control study. Rheumatology (Oxford) 52:487–493
Ohar JA, Cheung M, Talarchek J et al (2016) Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer. Cancer Res 76:206–215
Ostroff RM, Mehan MR, Stewart A et al (2012) Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One 7:e46091
Park EK, Thomas PS, Creaney J et al (2010) Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med 48:869–874
Park EK, Yates DH, Creaney J et al (2012) Association of biomarker levels with severity of asbestos-related diseases. Saf Health Work 3:17–21
Pass HI, Levin SM, Harbut MR et al (2012) Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 367:1417–1427
Pass HI, Lott D, Lonardo F et al (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353:1564–1573
Pass HI, Wali A, Tang N et al (2008) Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 85:265–272
Peipins LA, Lewin M, Campolucci S et al (2003) Radiographic abnormalities and exposure to asbestos-contaminated vermiculite in the community of Libby, Montana, USA. Environ Health Perspect 111:1753–1759
Pelclova D, Fenclova Z, Kacer P et al (2008) Increased 8-isoprostane, a marker of oxidative stress in exhaled breath condensate in subjects with asbestos exposure. Ind Health 46:484–489
Peluso I, Morabito G, Urban L et al (2012) Oxidative stress in atherosclerosis development: the central role of LDL and oxidative burst. Endocr Metab Immune Disord Drug Targets 12:351–360
Pilger A, Rudiger HW (2006) 8-Hydroxy-2′-deoxyguanosine as a marker of oxidative DNA damage related to occupational and environmental exposures. Int Arch Occup Environ Health 80:1–15
Pooley FD (1972) Electron microscope characteristics of inhaled chrysotile asbestos fibre. Br J Ind Med 29:146–153
Prazakova S, Thomas PS, Sandrini A et al (2014) Asbestos and the lung in the 21st Century: an update. Clin Respir J 8:1–10
Qi F, Okimoto G, Jube S et al (2013) Continuous exposure to chrysotile asbestos can cause transformation of human mesothelial cells via HMGB1 and TNF-alpha signaling. Am J Pathol 183:1654–1666
Ramos-Nino ME, Testa JR, Altomare DA et al (2006) Cellular and molecular parameters of mesothelioma. J Cell Biochem 98:723–734
Reid A, de Klerk NH, Magnani C et al (2014) Mesothelioma risk after 40 years since first exposure to asbestos: a pooled analysis. Thorax 69:843–850
Robinson BW, Creaney J, Lake R et al (2003) Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362:1612–1616
Rodriguez Portal JA, Rodriguez BE, Rodriguez RD et al (2009) Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomark Prev 18:646–650
Sandhu H, Dehnen W, Roller M et al (2000) MRNA Expression patterns in different stages of asbestos-induced carcinogenesis in rats. Carcinogenesis 21:1023–1029
Sartorelli P, Romeo R, Scancarello G et al (2007) Measurement of asbestos fibre concentrations in fluid of repeated bronchoalveolar lavages of exposed workers. Ann Occup Hyg 51:495–500
Schulze PC, Lee RT (2005) Oxidative stress and atherosclerosis. Curr Atheroscler Rep 7:242–248
Schurkes C, Brock W, Abel J et al (2004) Induction of 8-hydroxydeoxyguanosine by man made vitreous fibres and crocidolite asbestos administered intraperitoneally in rats. Mutat Res 553:59–65
Sekido Y (2013) Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 34:1413–1419
Selikoff IJ, Hammond EC, Seidman H (1980) Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 46:2736–2740
Serban C, Dragan S (2014) The relationship between inflammatory and oxidative stress biomarkers, atherosclerosis and rheumatic diseases. Curr Pharm Des 20:585–600
Snyder NW, Mesaros C, Blair IA (2015) Translational metabolomics in cancer research. Biomark Med 9:821–834
Stayner L, Welch LS, Lemen R (2013) The worldwide pandemic of asbestos-related diseases. Annu Rev Public Health 34:205–216
Sterman DH, Albelda SM (2005) Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 10:266–283
Swain WA, O'Byrne KJ, Faux SP (2004) Activation of p38 MAP kinase by asbestos in rat mesothelial cells is mediated by oxidative stress. Am J Phys Lung Cell Mol Phys 286:L859–L865
Tabata C, Kanemura S, Tabata R et al (2013a) Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma. J Clin Gastroenterol 47:684–688
Tabata C, Shibata E, Tabata R et al (2013b) Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer 13:205–211
Testa JR, Cheung M, Pei J et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43:1022–1025
Valavanidis A, Vlachogianni T, Fiotakis C (2009) 8-Hydroxy-2′-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 27:120–139
Vaught JD, Bock C, Carter J et al (2010) Expanding the chemistry of DNA for in vitro selection. J Am Chem Soc 132:4141–4151
Victor VM, Rocha M, Sola E et al (2009) Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 15:2988–3002
Wang H, Yang H, Tracey KJ (2004) Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 255:320–331
Wang Q, Zhang S, Guo L et al (2015) Serum apolipoprotein A-1 quantification by LC-MS with a SILAC internal standard reveals reduced levels in smokers. Bioanalysis 7:2895–2911
Wu L, Ortiz C, Xu Y et al (2015) In situ liquid cell observations of asbestos fiber diffusion in water. Environ Sci Technol 49:13340–13349
Wu X, Li D, Liu L et al (2014) Serum soluble mesothelin-related peptide (SMRP): a potential diagnostic and monitoring marker for epithelial ovarian cancer. Arch Gynecol Obstet 289:1309–1314
Xu J, Kadariya Y, Cheung M et al (2014) Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res 74:4388–4397
Yamada S, Inoue K, Yakabe K et al (2003) High mobility group protein 1 (HMGB1) quantified by ELISA with a monoclonal antibody that does not cross-react with HMGB2. Clin Chem 49:1535–1537
Yamada S, Tabata C, Tabata R et al (2011) Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med 49:1721–1726
Yang H, Rivera Z, Jube S et al (2010) Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A 107:12611–12616
Yoshida R, Ogawa Y, Shioji I et al (2001) Urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine and biopyrrins levels among construction workers with asbestos exposure history. Ind Health 39:186–188
Zangar RC, Daly DS, White AM (2006) ELISA microarray technology as a high-throughput system for cancer biomarker validation. Expert Rev Proteomics 3:37–44
Zhou Q, Zhu Z, Hu X et al (2016) HMGB1: A critical mediator for oxidized-low density lipoproteins induced atherosclerosis. Int J Cardiol 202:956–957
Acknowledgments
This work was supported by NIH grants P42ES023720, P30ES013508, and T32ES019851. The authors have no competing financial interests to disclose.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Mesaros, C., Weng, L., Blair, I.A. (2017). Biomarkers of Response to Asbestos Exposure. In: Testa, J. (eds) Asbestos and Mesothelioma. Current Cancer Research. Springer, Cham. https://doi.org/10.1007/978-3-319-53560-9_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-53560-9_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-53558-6
Online ISBN: 978-3-319-53560-9
eBook Packages: MedicineMedicine (R0)